News
Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...
US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...
US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...
S&P 500 posts first close above 6,300, Nasdaq hits a record ahead of big tech earnings: Live updates
U.S. stocks moved higher on Monday as optimism around earnings overshadowed any investor fears over the latest developments ...
Charles Schwab has expanded the list of securities available on its thinkorswim platform for overnight trading.
8h
Zacks Investment Research on MSNSRPT Down After Third Death in Muscular Dystrophy Gene Therapy ProgramShares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results